Originally published as JCO Early Release 10.1200/JCO.2004.10.028 on September 13 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gronlund, B. Articles by Hansen, H. H. Search for Related Content PubMed PubMed Citation Articles by Gronlund, B. Articles by Hansen, H. H. Pubmed/NCBI databases Medline Plus Health Information Ovarian Cancer Related Articles Related Editorial Social Bookmarking                            What's this?

Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma?

From the Departments of Oncology and Gynecology, Rigshospitalet, Copenhagen University Hospital; Department of Biostatistics, University of Copenhagen; the Department of Clinical Biochemistry, Statens Serum Institute; and Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark

Address reprint requests to Bo Gronlund, MD, Department of Oncology 5073, Rigshospitalet, DK-2100 Copenhagen, Denmark; e-mail: bo.gronlund{at}dadlnet.dk

PURPOSE: The aim of the study was to compare the prognostic value of a response by the Gynecologic Cancer Intergroup (GCIG) Cancer Antigen (CA) -125 response criteria and the Response Evaluation Criteria in Solid Tumors (RECIST) on survival in patients with ovarian carcinoma receiving second-line chemotherapy.

PATIENTS AND METHODS: From a single-institution registry of 527 consecutive patients with primary ovarian carcinoma, 131 records satisfied the inclusion criteria: ovarian carcinoma of International Federation of Gynecology and Obstetrics stage IC to IV, first-line chemotherapy with paclitaxel and a platinum compound, refractory or recurrent disease, and second-line chemotherapy consisting of topotecan or paclitaxel plus carboplatin. Univariate and multivariate analyses of survival were performed using the landmark method.

RESULTS: In patients with measurable disease by RECIST and with assessable disease by the CA-125 criteria (n = 68), the CA-125 criteria were 2.6 times better than the RECIST at disclosing survival. In a multivariate Cox analysis with inclusion of nine potential prognostic parameters, CA-125 response (responders v nonresponders; hazard ratio, 0.21; P < .001) and number of relapse sites (solitary v multiple; hazard ratio, 0.47; P = .020) were identified as contributory prognostic factors for survival, whereas the parameters of RECIST (responders v nonresponders), as well as the remaining variables, had nonsignificant prognostic impact.

CONCLUSION: The GCIG CA-125 response criteria are a better prognostic tool than RECIST in second-line treatment with topotecan or paclitaxel plus carboplatin in patients with ovarian carcinoma.

Supported by grants from the M. Kristjan and Margrethe Kjær Foundation, and the H:S Copenhagen Hospital Corporation (grant No. 24-03R), Copenhagen, Denmark.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Can We Now Agree to Use the Same Definition to Measure Response According to CA-125?
  Gordon J.S. Rustin
  JCO 2004 22: 4035-4036 [Full Text]

This article has been cited by other articles:

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]

				J. S. Rader, C. F. Aylsworth, D. A. Juckett, D. G. Mutch, M. A. Powell, L. Lippmann, and N. V. Dimitrov Phase I Study and Preliminary Pharmacology of the Novel Innate Immune Modulator rBBX-01 in Gynecologic Cancers Clin. Cancer Res., May 15, 2008; 14(10): 3089 - 3097. [Abstract] [Full Text] [PDF]

				F. Iten, B. Muller, C. Schindler, C. Rochlitz, D. Oertli, H. R. Macke, J. Muller-Brand, and M. A. Walter Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial Clin. Cancer Res., November 15, 2007; 13(22): 6696 - 6702. [Abstract] [Full Text] [PDF]

				M Candelaria, D Gallardo-Rincon, C Arce, L Cetina, J. Aguilar-Ponce, O Arrieta, A Gonzalez-Fierro, A Chavez-Blanco, E de la Cruz-Hernandez, M. Camargo, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Ann. Onc., September 1, 2007; 18(9): 1529 - 1538. [Abstract] [Full Text] [PDF]

				R. L. Coleman, A. Gordon, J. Barter, S. Sun, W. Rackoff, and T. J. Herzog Early Changes in CA125 After Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients Oncologist, January 1, 2007; 12(1): 72 - 78. [Abstract] [Full Text] [PDF]

				J.-F. Chatal, L. Campion, F. Kraeber-Bodere, S. Bardet, J.-P. Vuillez, B. Charbonnel, V. Rohmer, C.-H. Chang, R. M. Sharkey, D. M. Goldenberg, et al. Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group J. Clin. Oncol., April 10, 2006; 24(11): 1705 - 1711. [Abstract] [Full Text] [PDF]

				P. Viens, T. Petit, A. Yovine, P. Bougnoux, G. Deplanque, P.-H. Cottu, R. Delva, J.-P. Lotz, S. V. Belle, J.-M. Extra, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients Ann. Onc., March 1, 2006; 17(3): 429 - 436. [Abstract] [Full Text] [PDF]

				S. Ferretti, P. R. Allegrini, T. O'Reilly, C. Schnell, M. Stumm, M. Wartmann, J. Wood, and P. M.J. McSheehy Patupilone Induced Vascular Disruption in Orthotopic Rodent Tumor Models Detected by Magnetic Resonance Imaging and Interstitial Fluid Pressure Clin. Cancer Res., November 1, 2005; 11(21): 7773 - 7784. [Abstract] [Full Text] [PDF]

				S. Campos, O. Hamid, M. V. Seiden, A. Oza, M. Plante, R. K. Potkul, P. F. Lenehan, E. P. Kaldjian, M. L. Varterasian, C. Jordan, et al. Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer J. Clin. Oncol., August 20, 2005; 23(24): 5597 - 5604. [Abstract] [Full Text] [PDF]

				G. J.S. Rustin Can We Now Agree to Use the Same Definition to Measure Response According to CA-125? J. Clin. Oncol., October 15, 2004; 22(20): 4035 - 4036. [Full Text] [PDF]